Drug intelligence / Profile preview

SBP-102

Development stage: Preclinical
Lead developer: SML Biopharm
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous, Intramuscular

Overview

SBP-102 is an mRNA-based cancer vaccine and bispecific antibody (bsAb) therapeutic candidate being developed by SML Biopharm. Built on the company's proprietary mRNA/LNP (lipid nanoparticle) platform, SBP-102 is designed to treat Head and Neck Squamous Cell Carcinoma (HNSCC) by leveraging mRNA to express a bispecific antibody in vivo, thereby stimulating a targeted immune response against tumor cells. The program is currently in the candidate optimization stage and is categorized within SML Biopharm's 'Immune Response Based Therapeutics' portfolio.

Beyond the preview

Go deeper on SBP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-102.

Explore the full profile